CM
APLS

Cercano Management’s Apellis Pharmaceuticals APLS Stock Holding History

Cercano Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-99,912
Closed -$6.59M – 112
2023
Q1 		$6.59M Buy
+99,912
New +$5.77M 0.26% 67

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cercano Management's APLS Position: Q2 2023 in Review

Cercano Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 99,912 shares — an estimated $6.59M sold.

Cercano Management first reported a position in APLS in Q1 2023 and held it in 1 quarter. The position peaked at $6.59M in Q1 2023. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Cercano Management reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cercano Management sold 99,912 Apellis Pharmaceuticals shares in Q2 2023, an estimated $6.59M.
  • Cercano Management first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Cercano Management's Apellis Pharmaceuticals position peaked at $6.59M in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Cercano Management's 13F filing for Q2 2023, filed 2 Aug 2023.